NovelCD4/CD8 design delivers most comprehensive evaluation of patients’ immune response to tuberculosis infection Germantown, Maryland, and Hilden, Germany, October 5, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of its leading blood test for tuberculosis (TB) infection. QFT-Plus kits will be available... Read more
Assuring the highest accuracy in human identity testing for law enforcement and other uses Hilden, Germany, and Germantown, Maryland, October 02, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its manufacturing and supply chain for consumables and other products for forensic and human identity testing has been certified by Bureau Veritas, a leading... Read more
Hilden, Germany, and Germantown, Maryland, October 02, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its manufacturing and supply chain for consumables and other products for forensic and human identity testing has been certified by Bureau Veritas, a leading inspection agency, as meeting the latest international standards for products used in... Read more
OXFORD, United Kingdom and MARLBOROUGH, Mass., September 27, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision of the U.S. District Court for the District of Massachusetts in the Company’s patent infringement... Read more
VENLO, the Netherlands, September 6, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announces the successful completion of the following series of transactions: The issue of new senior unsecured cash settled convertible notes (the “Notes“) outside the United States for $400 million aggregate principal amount; and The entry into derivative transactions to... Read more
VENLO Netherlands, September 6, 2017 – The Management Board of QIAGEN N.V.(“QIAGEN” or the “Company”), with the consent of its Supervisory Board has resolved today to issue senior, unsecured cash settled convertible notes convertible into common shares of the Company (the “Notes”). The Company intends to place Notes in an aggregate volume of USD 350 million. The... Read more
VENLO, the Netherlands, September 6, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announces the successful completion of the following series of transactions: The issue of new senior unsecured cash settled convertible notes (the “Notes“) outside the United States for $400 million aggregate principal amount; and The entry into derivative transactions to increase... Read more
NEW YORK and HILDEN, Germany, (June 3, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies... Read more
FY 2015: Adjusted net sales $1.28 billion (+3% at constant exchange rates, -5% actual); adjusted operating income $315 million; adjusted EPS $1.05 ($1.13 CER) Adjusted net sales rise 6% CER excluding three percentage points of headwind from reduced U.S. HPV test sales Free cash flow rises 9% to $220 million Q4 2015: Adjusted net sales... Read more
June 22, 2017 – Saluggia, Italy; Hilden, Germany, and Germantown, Maryland – DiaSorin (FTSE Italy Mid Cap: DIA) and QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) announced today a new collaboration to develop new tests for DiaSorin’s LIAISON family of analyzers based on a review and selection process involving QIAGEN’s assay technologies. The adoption of... Read more